Oncosynergy

OncoSynergy is a clinical-stage immuno-oncology company in Stamford, Connecticut developing antibody therapeutics for solid and hematologic cancers. Its lead candidate, OS2966, is a first-in-class humanized and deimmunized pan-CD29 (beta-1 integrin) monoclonal antibody that targets tumor-microenvironment interactions driving treatment resistance. OS2966 entered a first-in-human Phase 1 trial in recurrent glioblastoma in 2020 and has received three FDA Orphan Drug Designations, the most recent in May 2024. The company was spun out of UCSF and incubated at JLABS South San Francisco.

OS2966 is a first-in-class anti-CD29 antibody targeting beta-1 integrin in the tumor microenvironment, a mechanism distinct from the checkpoint-inhibitor approaches that dominate immuno-oncology, and it holds three FDA Orphan Drug Designations.